EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib stands out as Exelixis’ most clinically advanced asset ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...

Equities research analysts at Zacks Research boosted their Q4 2024 earnings per share (EPS) estimates for Exelixis in a ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Exelixis gained an exclusive option to license XB002 (then ICON-2) in exchange for an upfront payment to Iconic of $7.5 million and a commitment of preclinical development funding.

Sairopa has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis (EXEL) involving ADU-1805, an anti-SIRPalpha antibody with the potential to enhance ...

Brookline initiated coverage of Exelixis (EXEL) with a Buy rating.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top ...